Skip to content

Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Non-small cell lung cancer

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
EU CTIS
Registry ID
CTIS2024-516189-12-00
Acronym
HCQHNLcancer
Enrollment
20
Registered
2024-07-29
Start date
Unknown
Completion date
2025-07-18
Last updated
2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

only Lung Squamous Cell Carcinoma or Adenocarcinoma)., or Resectable Non-small cell lung cancer (NSCLC, Patients affected by Resectable Head and Neck (HN) cancer (only Squamous Cell Carcinoma of the oral cavity or larynx)

Brief summary

The biological effect of HCQ will be evaluated using immunohistochemical studies performed for known autophagic and immunological markers (CD3, CD8, CD163, p53, p62, LC3) with quantification of positivity / total cells, intensity, expression pattern. Eventual tumor cytoarchitectural modification and tumor lymphocyte infiltrate will be evaluated and scored using standard grading system.

Interventions

DRUGHYDROXYCHLOROQUINE

Sponsors

Ospedale San Raffaele S.r.l.
Lead SponsorOTHER

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Design outcomes

Primary

MeasureTime frame
The biological effect of HCQ will be evaluated using immunohistochemical studies performed for known autophagic and immunological markers (CD3, CD8, CD163, p53, p62, LC3) with quantification of positivity / total cells, intensity, expression pattern. Eventual tumor cytoarchitectural modification and tumor lymphocyte infiltrate will be evaluated and scored using standard grading system.

Countries

Italy

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026